Skip to main content
SpringerLink
Log in

Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Central nervous system (CNS)-directed prophylactic intrathecal (IT) therapy is indicated in patients with Burkitt and acute lymphoblastic lymphoma. Its role in diffuse large B cell lymphoma (DLBCL), a heterogeneous subtype, is less well defined. While addition of rituximab to standard cyclophosphamide–hydroxydaunorubicin–oncovin–prednisone (CHOP) chemotherapy (R-CHOP) has improved the outcomes of DLBCL patients, its role in reducing CNS relapse is unclear. We aim to (1) evaluate the clinical risk factors predictive of CNS relapse, (2) the role of rituximab in influencing CNS relapse, and (3) role of intrathecal prophylaxis. Four hundred ninety-nine patients with DLBCL from 2000 to 2008 were included (CHOP 179 vs. R-CHOP 320). IT prophylaxis was administered to 82 patients based on our institution’s guidelines. Baseline characteristics between CHOP- and R-CHOP-treated patients were similar. Although R-CHOP significantly increased the complete remission rate from 71% to 81% (P < 0.01), CNS relapse rates remained unchanged (R-CHOP 6% vs. CHOP 5.1%). On multivariate analysis, poor performance status (Eastern Cooperative Oncology Group >1; hazard ratio (HR) = 2.01, 95% confidence interval (CI) 1.29–3.14), failure to attain remission (non-complete response (CR) vs. CR: HR = 2.39, 95% CI = 1.03 to 5.51), testicular (HR = 6.67, 95% CI = 1.62 to 27.53), kidney (HR = 20.14, 95% CI = 5.23 to 77.46), and breast involvement (HR = 6.14, 95% CI = 1.61 to 23.37) were each independently predictive of CNS relapse. Use of IT prophylaxis did not appear to decrease CNS relapse. Median survival after CNS relapse was 3.2 months. CNS relapse, a fatal event, remains a challenge in R-CHOP-treated patients. IT prophylaxis may not be sufficient to reduce CNS relapse, and strategies including systemic agents with high CNS penetration should be evaluated in high-risk patients identified in this study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ (2010) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 21:1046–1052

    Article  PubMed  CAS  Google Scholar 

  2. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocol of German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol 18:149–157

    Article  PubMed  CAS  Google Scholar 

  3. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M (2009) CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 113:3896–3901

    Article  PubMed  CAS  Google Scholar 

  4. Shimazu T, Notohara K, Ueda Y (2009) Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single centre experience. Int J Hematol 89:577–583

    Article  PubMed  CAS  Google Scholar 

  5. Doolittle ND, Abrey LE, Zucca E, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, Soussain C, Johnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Df K, Zucca E (2008) Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood 111:1085–1093

    Article  PubMed  CAS  Google Scholar 

  6. Van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F (1998) Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998:1178–1184

    Google Scholar 

  7. Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI (2009) Natural history of CNS relapse in patients with aggressive non-Hodgkin lymphoma: a 20-year follow up analysis of SWOG 8516—The Southwest Oncology Group. J Clin Oncol 27:114–119

    Article  PubMed  Google Scholar 

  8. Arkenau HT, Chong G, Cunningham D, Watkins D, Agarwal R, Sirohi B, Trumper M, Norman A, Wotherspoon A, Horwich A (2007) The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol 18:541–545

    Article  PubMed  Google Scholar 

  9. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med 346:235–242

    Article  PubMed  CAS  Google Scholar 

  10. Feugier P, Van Hoof A, Sebban C et al (2005) Long term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de I’Adulte. J Clin Oncol 23:4117–4126

    Article  PubMed  CAS  Google Scholar 

  11. Pfreundshcuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391

    Article  Google Scholar 

  12. Haberman TM, Weller EA, Morrison VA et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121–3127

    Article  Google Scholar 

  13. Pfreundshcuh M, Schubert Z, Ziepert M et al (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol 9:105–116

    Article  Google Scholar 

  14. Yamamoto W, Ishigatsubo Y et al (2010) Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Hematol 85:6–10

    CAS  Google Scholar 

  15. Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, Dunleavy K, Jaffe Es, Abati A, Stetler-Stevenson M, Wilson WH (2005) High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for CNS involvement: the role of flow cytometry versus cytology. Blood 105:496–502

    Article  PubMed  CAS  Google Scholar 

  16. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non Hodgkin lymphoma. Blood 102:4284–4289

    Article  PubMed  CAS  Google Scholar 

  17. Gokbuget N, Hoelzer D (2002) Recent approaches in acute lymphoblastic leukemia in adults. Rev Clin Exp Hematol 6:114–140

    Article  PubMed  Google Scholar 

  18. Gokbuget N, Hoelzer D (1998) Meningeosis leukaemia in adult acute lymphoblastic leukaemia. J Neuro Oncol 38:167–180

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, National Cancer Centre, 11 Hospital Drive, Singapore, 169610, Singapore

    W. M. Tai, J. Chung, P. L. Tang, Y. X. Koo, K. W. Tay, R. Quek, M. Tao & S. T. Lim

  2. Division of Clinical Trials and Epidemiology Science, Singapore, Singapore

    X. Hou

Authors
  1. W. M. Tai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. L. Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. X. Koo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. X. Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. W. Tay
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Quek
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. T. Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to W. M. Tai or S. T. Lim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tai, W.M., Chung, J., Tang, P.L. et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol 90, 809–818 (2011). https://doi.org/10.1007/s00277-010-1150-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-010-1150-7

Keywords

Search

Navigation